Alterations of non-esterified fatty acids, β-hydroxybutyric acid, urea, and bilirubin traits in clinical endometritis cows following treatment

AbstractThe aim of the present study was to evaluate the relationship between bovine metabolic parameters and severity of clinical endometritis and the likelihood of recovery from endometritis following PGF2 α therapy. Clinical endometritis was diagnosed by ultrasonographic examination from 26 to 32 days postpartum (day 0 of experiment) and on presence of uterine discharge. The severity of endometritis was classified on a 3-point scale. Those cows with a corpus luteum (n = 113), received PGF2α (LUTALYSE, Pfizer, Australia) on day 0. Serum non-esterified fatty acids (NEFA), β-hydroxybutyric acid (BHBA), urea, and direct and total bilirubin concentrations of endometritis cows were measured on days 0, 7, and 14 of the experiment. Clinical recovery was evaluated on day 14. Recovered (RC) cows had lower NEFA values than unrecovered (URC) ones irrespective of the grade at days 7 and 14 (P 
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

Publication date: Available online 21 November 2019Source: Journal of Cancer PolicyAuthor(s): Brandon Maser, Lisa M. Force, Paola Friedrich, Federico Antillon, Ramandeep S. Arora, Cristian A. Herrera, Carlos Rodriguez-Galindo, Rifat Atun, Avram DenburgAbstractTo help understand how health systems and sociopolitical contexts intersect with and impact the performance of childhood cancer care in low- and middle-income countries (LMICs), we have developed a systems-level framework for analyzing the performance of LMIC childhood cancer programs within their health system contexts: The Paediatric Oncology System Integration Tool...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Date: Thursday, 12 12, 2019; Speaker: Julie Blendy , Ph.D. Professor of Pharmacology, Perelman School of Medicine, University of Pennsylvania; Building: Building 40; 1201/1203
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 12 19, 2019; Speaker: Cristine Delnevo, Ph.D., M.P.H., F.A.A.H.B., Director, Center for Tobacco Studies, Society and Policy Rutgers School of Public Health; Nir Eyal, D.Phil, Director, Center for Population-Level Bioethics (CPLB), Society and Policy Rutgers School of Public Health; https://epi.grants.cancer.gov/events/enrich-forum/
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Monday, 01 27, 2020; Speaker: Lisa Ingraham, Ph.D., University of California, San Francisco; Porter Neuroscience Bldg, 35a; G620-640; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Friday, 11 22, 2019; Speaker: various; Building 38; Conference room B, second floor
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Friday, 11 22, 2019; Speaker: Nicola Santoro, MD, PhD, Assistant Professor of Pediatrics (Endocrinology), Yale School of Medicine; Building 10 CRC; FAES 1&2
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Monday, 11 25, 2019; Speaker: Eugene M. Oltz , Chair of the Department of Microbial Infection and Immunity , College of Medicine – The Ohio State University; 37; 6041
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Australia Health | Bilirubin | Pathology | Pfizer | Study